Canaccord raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $143 from $140 and keeps a Buy rating on the shares. The firm said the company delivered a topline beat for 1Q26 driven by a sequential increase in BBS patients and patients on reimbursed therapy globally.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM: